

**AMENDMENTS TO THE CLAIMS:**

This listing of claims will replace all prior versions, and listings, of claims in the application:

**LISTING OF CLAIMS:**

Claims 1-31 (Canceled).

Claim 32 (Currently Amended) ~~The polypeptide according to claim 31~~ A purified polypeptide comprising at least one T epitope from a liver-stage specific protein produced by *P. falciparum*, wherein said T epitope has an amino acid sequence selected from the group of the amino acid sequence of SEQ ID NOS: 39-46.

Claims 33-34 (Canceled).

Claim 35 (Currently Amended) ~~The polypeptide of claim 31~~ claim 32, further comprising at least one B epitope from a liver-stage specific protein produced by *P. falciparum*.

Claims 36-38 (Canceled).

Claim 39 (Currently Amended) A synthetic polypeptide comprising at least one T epitope from a liver-stage specific protein produced by *P. falciparum*, wherein said T epitope has an amino acid sequence selected from the group of the amino acid sequence of SEQ ID NOS: 39-46.

Claims 40-41.

Claim 42 (Currently Amended) ~~The immunogenic composition directed against malaria according to claim 41~~ An immunogenic composition directed against malaria comprising a molecule having one or more peptide sequences bearing all or part of one or more T epitopes resulting from the infectious activity of *P. falciparum* in hepatic cells, wherein said T epitope is selected from the group of: an amino acid sequence of SEQ ID NOS: 39-42, an amino acid sequence of SEQ ID NOS: 43-46 and amino acid sequence of SEQ ID NO: 19.

Claim 43 (Previously Presented) An immunogenic composition directed against malaria comprising a molecule having one or more peptide sequences bearing all or part of one or more T epitopes resulting from the infectious activity of *P. falciparum* in the hepatic cells, wherein said T epitope is selected from the group of: an amino acid sequence of SEQ ID NOS: 39-42, an amino acid sequence of SEQ ID NOS: 43-46 and amino acid sequence of SEQ ID NO: 19.